Neuropathix Inc, based in Doylestown, PA, is a biopharmaceutical company specializing in the research and development of innovative therapeutics for the treatment of neurodegeneration, oxidative stress, and neuropathic pain-related diseases. With a focus on addressing serious unmet medical needs, Neuropathix is committed to engineering novel and proprietary targeted therapies to provide effective pain management options for patients.
Through their subsidiary, Kannalife Sciences, Neuropathix has made significant advancements in the discovery and development of patented cannabinoid-inspired molecules. Their research has resulted in the creation of KLS-13019 and other New Chemical Entities (NCEs) that are up to 200 times more potent, 10 times more bioavailable, 5 times safer, and 1000 times more effective than CBD. With a science-based and data-driven approach, Neuropathix aims to improve the lives of patients suffering from conditions such as Chemotherapy Induced Peripheral Neuropathy, Hepatic Encephalopathy, Mild Traumatic Brain Injury, and chronic pain.
Generated from the website